Clinical effects of trithiozine, a newer gastric anti-secretory agent.
Trithiozine is a new product which in animal studies proved to have a marked anti-secretory and anti-ulcer effect, along with a very low acute and chronic toxicity and no ganglioplegic, anticholinergic and anti-H2 activity. Clinical trials with trithiozine have been performed in some European countries. The results of these trials, most of which were conducted on a double-blind basis, and including already several hundreds of patients, have shown that oral trithiozine: exerts a very significant action on both basal and stimulated gastric acid secretion, without a rebound hypersecretion; promotes, in most patients, a complete endoscopic healing of peptic ulcer, in addition to an early symptomatic relief; has a mild sedative action; does not affect the pancreatic secretion; is well tolerated even for long-term (up to 10 months) treatments.
D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002927:Cimetidine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003864:Depression, Chemical; D004311:Double-Blind Method; D005750:Gastric Juice / Q000378:metabolism*; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000188:drug therapy*; D010919:Placebos; D011413:Propantheline / Q000627:therapeutic use
D000897:Anti-Ulcer Agents; D009025:Morpholines; D010919:Placebos; D011413:Propantheline; D002927:Cimetidine